Sunday - October 4, 2026

RNAi Agents and Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), and Methods of Use

2026-09-08

ALEXANDRIA, Virginia, Sept. 8 -- ARROWHEAD PHARMACEUTICALS, INC., Pasadena, California has been assigned a patent (No. US 12729377 B2, initially filed April 15, 2021) developed by three inventors Zhen Li, San Diego, California; Rui Zhu, San Diego, California; and So Wong, Oregon, Wisconsin, for "RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use." . . .

Information Request Form

Name:
Category that best fits the type of business or agency you are affiliated with:	Government Newspaper / Media Business Public Policy Individual / Student Educators
Company Name:
Email:
Phone:
State:

I'd like to have a copy of this article mailed to me.

To also receive a free sample of other Targeted News products check the appropriate boxes below.
Golf Handicap site (FairwayFiles.com)
Products marked with ** can be customized by keywords or areas of interest. If you select them please specify your keywords in the box below:

If we need to contact you please specify your preferred contact method. Have a representative contact me by phone
Have a representative contact me via email

Additonal questions or comments:

Click here for more information or a free trial

Existing Customer Login

RNAi Agents and Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), and Methods of Use

Information Request Form

Copyright Targeted News Service 2026